4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
NervGen Pharma Corp. (NGEN) operates in the Biotechnology industry and is headquartered in Vancouver, Canada with about 9 employees. Its market capitalization is roughly $184 million. In the fiscal year ended 2025-12-31, NGEN reported $0M in revenue and ($44M) in net income.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($25M) | ($25M) | ($18M) | ($23M) | — |
| Net Income | ($44M) | ($24M) | ($22M) | ($21M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($8M) | ($6M) | ($6M) | ($6M) | ($6M) | — |
| Net Income | ($2M) | ($27M) | ($4M) | ($9M) | ($4M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $23M | $20M | $13M | $24M | — |
| Total Liabilities | $20M | $17M | $15M | $10M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NGEN viewer.
About TickerBase · Data methodology & sources